The bigger safety concern is false reliance: using ineffective OTC products delays access to evidence-based alternatives
Strategies to mitigate muscle loss include: Prioritizing protein at each meal before other macronutrients Incorporating resistance training at least 23 times weekly Monitoring body composition, not just scale weight Working with your healthcare provider if side effects prevent adequate nutritionnever adjust medication doses on your own Contact your healthcare provider immediately if you experience: Severe or persistent nausea, vomiting, or abdominal pain Signs of dehydration (extreme thirst, dizziness, dark urine) Low blood sugar symptoms (if taking insulin or sulfonylureas) Inability to eat or drink for more than 24 hours Selecting appropriate protein sources is essential for patients on GLP-1 therapy, particularly given the reduced appetite and early satiety these medications produce

Key Safety Checkpoints Before Starting GLP-1 Therapy Before initiating any GLP-1 medication, Crohn's patients must confirm disease remission or minimal inflammation through recent lab work (CRP, fecal calprotectin) and imaging if available
Then, all animals were euthanized by bleeding after transection of the abdominal vena cava under anesthesia and the liver, heart, soleus muscle, gastrocnemius muscle, tibialis anterior muscle, extensor digitorum longus muscle, epididymal white adipose tissue, and brown adipose tissue were harvested and immersed in RNAlater solution (Qiagen, Venlo, Netherlands) for qPCR analysis
Studies that looked at prognosis or chemoresistance were excluded
Active Ingredients Per 1 ml